DMK Pharmaceuticals Corporation Common Stock
DMK was delisted on the 6th of February, 2024.
21 hedge funds and large institutions have $11.8M invested in DMK Pharmaceuticals Corporation Common Stock in 2014 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 4 closing their positions.
163% more capital invested
Capital invested by funds: $4.49M → $11.8M (+$7.31M)
75% more call options, than puts
Call options by funds: $21K | Put options by funds: $12K
50% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 4
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
11% more funds holding
Funds holding: 19 → 21 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$629K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$173K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
+$72.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$37.5K |
| 5 |
BA
Bard Associates
Chicago,
Illinois
|
+$27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GP
Grow Partners
San Diego,
California
|
-$1.78M |
| 2 |
HighTower Advisors
Chicago,
Illinois
|
-$77.2K |
| 3 |
Goldman Sachs
New York
|
-$63.8K |
| 4 |
Jane Street
New York
|
-$50K |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$47K |
DMK Hedge Fund Activity: Q4 2014 in Review
21 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in DMK Pharmaceuticals Corporation Common Stock (DMK) for Q4 2014, worth a combined $11.8M — up 163% from $4.49M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new DMK positions and 4 closed out — a net gain of 2 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Marshall Wace, adding an estimated $629K. The largest seller was Grow Partners, exiting entirely with an estimated $1.78M sold.
- 21 institutional investors held DMK Pharmaceuticals Corporation Common Stock (DMK) as of Q4 2014, up from 19 in Q3 2014.
- Funds reported $11.8M of DMK Pharmaceuticals Corporation Common Stock stock for Q4 2014, up 163% quarter-over-quarter.
- 6 funds opened new DMK Pharmaceuticals Corporation Common Stock positions in Q4 2014 and 4 closed out, a net change of +2 holders.
- The largest DMK Pharmaceuticals Corporation Common Stock buyer in Q4 2014 was Marshall Wace, an estimated $629K added.
- The largest DMK Pharmaceuticals Corporation Common Stock seller in Q4 2014 was Grow Partners, an estimated $1.78M sold.
Based on aggregated 13F filings for Q4 2014.